MMP inhibition blocks fibroblast-dependent skin cancer invasion, reduces vascularization and alters VEGF-A and PDGF-BB expression

Anticancer Research

Volumn 30, Issue 3, 2010, Pages 703-712

  Woenne, Eva C ^a   Lederle, Wiltrud ^b   Zwick, Stefan ^a   Palmowski, Moritz ^b   Krell, Hans ^c   Semmler, Wolfhard ^a   Mueller, Margareta M ^a   Kissling, Fabian ^b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

Angiogenesis; Cytokine; Fibroblast; Imaging; MMP inhibition

Indexed keywords

COLLAGEN; GELATINASE A; INTERSTITIAL COLLAGENASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; PLATELET DERIVED GROWTH FACTOR BB; RO 28 2653; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INVASION; COLLAGEN DEGRADATION; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CANCER; UPREGULATION; VASCULARIZATION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; COLLAGEN; FIBROBLASTS; HUMANS; MATRIX METALLOPROTEINASES, SECRETED; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; ORGANIC CHEMICALS; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PYRIMIDINES; SKIN NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77951077643     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Liotta LA and Kohn EC: The microenvironment of the tumour-host interface. Nature 411: 375-379, 2001.
2. Dong-Le Bourhis X, Berthois Y, Millot G, Degeorges A, Sylvi M, Martin PM and Calvo F: Effect of stromal and epithelial cells derived from normal and tumorous breast tissue on the proliferation of human breast cancer cell lines in co-culture. Int J Cancer 71: 42-48, 1997.
3. Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD and Cunha GR: Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59: 5002-5011, 1999.
4. Kalluri R and Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 6: 392-401, 2006.
5. Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med 6: 669-676, 2003.
6. Lederle W, Stark HJ, Skobe M, Fusenig NE and Mueller MM: Platelet-derived growth factor-BB controls epithelial tumor phenotype by differential growth factor regulation in stromal cells. Am J Pathol 169: 1767-1783, 2006.
7. Kitadai Y, Sasaki T, Kuwai T, Nakamura T, Bucana CD, Hamilton SR and Fidler IJ: Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential. Int J Cancer 119: 2567-2574, 2006.
8. Rundhaug JE: Matrix metalloproteinases, angiogenesis, and cancer. Clin Cancer Res 9: 551-554, 2003.
9. Medina C, Videla S, Radomski A, Radomski MW, Antolín M, Guarner F, Vilaseca J, Salas A and Malagelada JR: Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis. Am J Physiol Gastrointest Liver Physiol 284: 116-122, 2003.
10. Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, Harper J, Tamvakopoulos G and Moses MA: Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci USA 97: 3884-3889, 2000.
11. Egeblad M and Werb Z: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174, 2002.
12. Coussens LM, Fingleton B and Matrisian LM: Matrix metalloproteinase inhibitors and cancer: Trails and tribulations. Science 295: 2387-2392, 2002.
13. Grams F, Brandstetter H, D'Alò S, Geppert D, Krell HW, Leinert H, Livi V, Menta E, Oliva A, Zimmermann G, Gram F, Brandstetter H, D'Alò S, Geppert D, Krell HW, Leinert H, Livi VMenta E, Oliva A and Zimmermann G: Pyrimidine-2,4,6-triones: a new effective and selective class of matrix metalloproteinase inhibitors. Biol Chem 382: 1277-1285, 2001.
14. Lein M, Jung K, Ortel B, Stephan C, Rothaug W, Juchem R, Johannsen M, Deger S, Schnorr D, Loening S and Krell HW: The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene 21: 2089-2096, 2002.
15. Vosseler S, Mirancea N, Bohlen P, Mueller MM and Fusenig NE: Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res 65: 1294-1305, 2005.
16. Breitkreutz D, Mirancea N, Schmidt C, Beck R, Werner U, Stark HJ, Gerl M and Fusenig NE: Inhibition of basement membrane formation by a nidogen-binding 1 aminin gamma1-chain fragment in human skin-organotypic cocultures. J Cell Sci 15: 2611-2622, 2004.
17. Palmowski M, Huppert J, Hauff P, Reinhardt M, Schreiner K, Socher MA, Hallscheidt P, Kauffmann GW, Semmler W and Kiessling F: Vessel fractions in tumor xenografts depicted by flow- or contrast-sensitive 3D high-frequency Doppler ultrasound respond differently to multispecific tyrosine kinase receptor inhibition. Cancer Res 68: 7042-7049, 2008.
18. Zwick S, Strecker R, Kiselev V, Gall P, Huppert J, Palmowski M, Lederle W, Woenne EC, Hengerer A, Taupitz M, Semmler W and Kiessling F: Assessment of vascular remodeling under antiangiogenic therapy using DCE-MRI and vessel size imaging. J Magn Reson Imaging 29: 1125-1133, 2009.
19. Zhang C, Jugold M, Woenne EC, Lammers T, Morgenstern B, Mueller MM, Zentgraf H, Bock M, Eisenhut M, Semmler W and Kiessling F: Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res 67: 1555-1562, 2007.
20. Troprès I, Grimault S, Vaeth A, Grillon E, Julien C, Payen JF, Lamalle L and Décorps M: Vessel size imaging. Magn Reson Med 45: 397-408, 2001.
21. Beacham DA and Cukierman E: Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression. Semin Cancer Biol 15: 329-341, 2005.
22. De Wever O, Demetter P, Mareel M and Bracke M: Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 75: 2229-2238, 2008.
23. Carmeliet P and Jain RK: Angiogenesis in cancer and other diseases. Nature 407: 249-257, 2000.
24. Pilcher BK, Dumin JA, Sudbeck BD, Krane SM, Welgus HG and Parks WC: The activity of collagenase-1 is required for keratinocyte migration on a collagen type I matrix. J Cell Biol 37: 1445-1457, 1997.
25. Szabowski A, Maas-Szabowski N, Andrecht S, Kolbus A, Schorpp-Kistner M, Fusenig NE and Angel P: c-Jun and JunB antagonistically control cytokine-regulated mesenchymal-epidermal interaction in skin. Cell 103: 745-755, 2000.
26. Ingvarsen S, Madsen DH, Hillig T, Lund LR, Holmbeck K, Behrendt N and Engelholm LH: Dimerization of endogenous MT1-MMP is a regulatory step in the activation of the 72-kDa gelatinase MMP-2 on fibroblasts and fibrosarcoma cells. Biol Chem 389: 943-953, 2008.
27. Shah FD, Shukla SN, Shah PM, Shukla HK and Patel PS: Clinical significance of matrix metalloproteinase 2 and 9 in breast cancer. Indian J Cancer 246: 194-202, 2009.
28. Taniwaki K, Fukamachi H, Komori K, Ohtake Y, Nonaka T, Sakamoto T, Shiomi T, Okada Y, Itoh T, Itohara S, Seiki M and Yana I: Stroma-derived matrix metalloproteinase (MMP)-2 promotes membrane type 1-MMP-dependent tumor growth in mice. Cancer Res 67: 4311-13419, 2007.
29. Barrientos S, Stojadinovic O, Golinko MS, Brem H and Tomic-Canic M: Growth factors and cytokines in wound healing. Wound Repair Regen 16: 585-601, 2008.